When was Faron Pharmaceuticals founded?

Faron Pharmaceuticals was founded in 2007 and raised its 1st funding round 9 years after it was founded.

Where is Faron Pharmaceuticals located?

Faron Pharmaceuticals is headquartered in Turku, Finland.

Who is the current CEO of Faron Pharmaceuticals?

Markku Jalkanen of Faron Pharmaceuticals. They have also founded 1 company.

How many employees does Faron Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at Faron Pharmaceuticals is 60.

Is Faron Pharmaceuticals a funded company?

Faron Pharmaceuticals is a funded company, having raised an undisclosed amount across 17 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Sep 21, 2016.

When was the latest funding round of Faron Pharmaceuticals?

Faron Pharmaceuticals' latest funding was a €***** Post IPO round on Apr 03, 2025, with participation from 1 investor.

Where does Faron Pharmaceuticals rank among its competitors?

Faron Pharmaceuticals ranks 407th amongst 3371 active competitors, of which 1129 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Faron Pharmaceuticals?

Faron Pharmaceuticals' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Faron Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Faron Pharmaceuticals is a public company based in Turku (Finland), founded in 2007 by Markku Jalkanen. It operates as a Clinical-stage developing immunotherapy for cancer, aorta aneurysm & ARDS. Faron Pharmaceuticals has raised an undisclosed amount in funding. The company has 3371 active competitors, including 1129 funded and 784 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Faron is a clinical-stage biopharmaceutical company developing drugs for acute organ traumas, vascular damage, and cancer immunotherapy. The pipeline consists of drug candidates (FP-1201-LYO and FP-1305) from two major Faron programmes – Traumakine® and Clevegen®, respectively. The indication of Traumakine (recombinant human IFN beta-1a) is acute respiratory distress syndrome (ARDS) & undergoing phase III clinical trials for the same. In addition, phase II trial is underway for the rupture of abdominal aorta aneurysm (RAAA). The second candidate, Clevegen® is a pre-clinical anti-Clever-1 antibody. It has the ability to switch immune suppression to immune activation in various conditions, This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (TIET). The molecule has the potential indication for oncology, infectious disease, and vaccine development.

Website: faron.com
Email ID: *****@faron.com
Phone Number: +358 **********, +358 **********

Key Metrics

Founded Year

2007

Location

Turku, Finland

Stage

Public

Latest Funding Round

Post IPO, Apr 03, 2025, €*****

Investors

IPF Partners & 6 more

Ranked

407^th among 3371 active competitors

Employee Count

60 as on Sep 30, 2026

Similar Companies

BeiGene & 608 more

Exit Details

Public

View Faron Pharmaceuticals' full profile

Faron Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Faron Pharmaceuticals Oy CIN: 2068285-4 , Finland, Active	Oct 24, 2006	-	-	-
Faron Europe GmbH CIN: 1342478 , Switzerland, Active	Apr 25, 2023	-	-	-
FARON USA LLC CIN: 824590360 , United States, Active	Dec 31, 1999	-	2 (As on Dec 31, 2023)	-

Faron Pharmaceuticals got listed on Nov 17, 2015.

Click here to take a look at Faron Pharmaceuticals's IPO in detail

Faron Pharmaceuticals has raised funding over 17 rounds. Its first funding round was on Sep 21, 2016. Its latest funding round was a Post IPO round on Apr 03, 2025 for €*****. 1 investor participated in its latest round. Faron Pharmaceuticals has 6 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Faron Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 03, 2025	9027634	Post IPO	7575807	1152858	7093685	6404869
Feb 06, 2025	5236805	Post IPO	1533255	5086287	1000798	8392969
Aug 13, 2024	5006113	Grant (prize money)	2464959	4841099	4054403	Defense.gov

Access funding benchmarks and valuations. Sign up today!

View details of Faron Pharmaceuticals's funding rounds and investors

The founders of Faron Pharmaceuticals is Markku Jalkanen. Markku Jalkanen is the CEO of Faron Pharmaceuticals.

Here are the details of Faron Pharmaceuticals' key team members:

Markku Jalkanen: Founder & CEO of Faron Pharmaceuticals.

View details of Faron Pharmaceuticals's Founder profiles and Board Members

Faron Pharmaceuticals' employee count trend

Faron Pharmaceuticals has 60 employees as of Sep 26. Here is Faron Pharmaceuticals's employee count trend over the years:

Employee count trend for Faron Pharmaceuticals

Uncover Faron Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Faron Pharmaceuticals include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Faron Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
407th	Faron Pharmaceuticals 2007, Turku (Finland), Public	Clinical-stage developing immunotherapy for cancer, aorta aneurysm & ARDS	-	IPF Partners, Heights Capital & 5 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Faron Pharmaceuticals's competitors? Click here to see the top ones

Faron Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on Faron Pharmaceuticals's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Faron Pharmaceuticals

Media has covered Faron Pharmaceuticals for a total of 24 events in the last 1 year, 10 of them have been about company updates and 3 about partnerships.